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Objectives. Our primary objective was to compare the effects of 
three different doses of caudoxatrilat with the effects of placebo on 
urinary volume in patients with moderately severe heart failure. 
The effects of candoxatrilat on urinary composition, neuroendo- 
crine indexes and renal hemodynamic function were also studied. 
Background. Candoxatrilat, a neutral endopeptidase inhibitor, 
reduces degradation of atrial natriuretic peptide and provokes 
diuresis in patients with mild heart failure, but the renal effects 
have not been studied in patients with moderately severe heart 
failure in a placebo-controlled study. 
Methods. In a double-blind crossover trial, the effects of 
intravenous boluses of saline vehicle (placebo) and 50, 100 and 
200 mg of candoxatrilat were compared on separate days in 12 
patients with heart failure. Urinary output and composition were 
measured for 8 h. Renal blood flow and glomerular filtration rate 
were determined by radionuclide techniques. Blood was with- 
drawn for the measurement of hormones before and 3 h after 
dosing. 
Results. All doses of candoxatrilat increased urinary volume 
(e.g., [mean -+ SEM] 263 + 53 to 490 -+ 82 ml for saline solution 
and the 200-mg dose, respectively, p < 0.01) and sodium content 
(14 + 4 to 37 -+ 11 retool, p < 0.001) in the 1st 4 h after dosing. 
Plasma atrial natriuretic peptide increased (140 -+ 26 to 279 -+ 
37 pg/ml, p < 0.01), whereas aldosterone decreased (178 -+ 41 to 
125 -+ 35 pg/ml, p < 0.01), and renin activity was unchanged (10 + 
2 to 12 + 3 ng/ml per h). 
Conclusions. Candoxatrilat given acutely causes diuresis, even 
in patients with moderately severe heart failure. 
(JAm Coil Cardiol 1995;25:1273-81) 
The biologic actions of atrial natriuretic peptide include 
natriuresis-diuresis, vasorelaxation a d inhibition of the renin- 
angiotensin system (1). Plasma levels of atrial natriuretic 
peptide are elevated in patients with heart failure in propor- 
tion to the degree of myocardial dysfunction (2), representing 
a compensatory response tending to reduce the hemodynamic 
load. 
Therapeutic use of the peptide is limited by its short plasma 
half-life (2 to 3 rain) and its susceptibility o degradation i  the 
gut (1). Another approach is to inhibit the enzymatic degra- 
dation of the peptide by neutral endopeptidase EC3.4.24.11 
(3), an important clearance pathway for circulating atrial 
natriuretic peptide. Studies in animals have shown that neutral 
endopeptidase inhibition enhances and prolongs the natri- 
uretic and hypotensive effects of coinfused exogenous atrial 
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natriuretic peptide (4) and increases odium excretion in 
animal models of hypertension a d heart failure (5,6). 
Given to healthy volunteers and patients with essential 
hypertension, i  whom plasma trial natriuretic peptide levels 
are normal or only modestly elevated, neutral endopeptidase 
inhibitors approximately double sodium excretion (7). A larger 
natriuresis (up to six-fold) has been reported in hypertensive 
patients on a high sodium diet (8), a circumstance associated 
with high levels of atrial natriuretic peptide, and prominent 
effects might also be anticipated in heart failure (9). 
In preliminary studies (10,11) _+candoxatrilat (UK-69,578, 
the racemic mixture of which candoxatrilat is the active 
component) and sinorphan have reduced pulmonary capillary 
wedge pressure and right atrial pressure in patients with mild 
to moderate heart failure. In addition, Northridge t al. (11) 
observed a 2.5-fold increase in sodium excretion produced by 
neutral endopeptidase inhibition in patients with mild heart 
failure (New York Heart Association functional classes I and 
II). In a small open study without placebo control, Mfinzel et 
al. (12) reported that candoxatrilat produced iuresis and 
natriuresis in patients with moderately severe heart failure 
(12). The present study was designed to examine in detail the 
acute renal response to candoxatrilat, a potent selective inhib- 
itor of neutral endopeptidase, given as a single bolus to 
patients with moderate to severe heart failure in a double-blind 
randomized trial. 
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Table l. Patient Characteristics at Baseline 
Daily Dose (mg) 
Serum 
Pt Age (yr)/ ACE Creatinine NYHA 
No. Gender Diagnosis EF (%) Furosemide Inhibitor (p, mol/liter) Class 
1 48/M DCM 15 40 15. enalapril 121 III 
2 52/M [HD 24 120 - -  88 I[ 
3 64/M IHD 25 - -  37.5, captopril 93 II 
4 5(I/M [HD 17 40 10. enalapril 148 II1 
5 56/M DCM 40 80 5. enalapril 103 II 
6 68/M DCM 23 la0 15, enalapril 106 III 
7 65/M DCM 31 120 10, enalapril 175 lll 
8 59/M IHD 39 1[10 25, captopril 118 III 
9 57/M IHD 15 120 - -  97 III 
10 72/M IHD 24 S0 37.5, captopril 159 II 
11 63/M Mitral 25 40 20, lisinopril 138 Ill 
regurgitation 
12 54/M IHD 33 80 - -  117 II 
ACE angiotensin-converting e zyme; DCM = dilated cardiomyopathy; EF = left ventricular ejection fraction; 
IHD - ischemic heart disease; M - male; NYHA Class - New York Heart Association functional class; Pt = patient. 
Methods  
Patients (Table 1). To enter the study, patients had to have 
a history of heart failure, be receiving treatment for that 
indication and have evidence of left ventricular dysfunction as 
evidenced by an echocardiographic end-diastolic dimension 
>58 mm and fractional shortening <20% or an ejection 
fraction <30% on multiple uptake gated acquisition radionu- 
elide ventriculography. Patients had to be in functional class lI 
or III, have a serum creatinine level >200 retool/liter and B1 
sinus rhythm or well controlled atrial fibrillation. 
Twelve men, mean age 59 years (range 48 to 72), with 
chronic heart failure were studied. All patients had a history of 
prior episodes of pulmonary edema, but their condition had 
subsequently stabilized with medical therapy. At the time of 
recruitment into the study, 10 patients gave a recent history of 
orthopnea, 7 were breathless on moderate exertion and 4 were 
breathless on slight exertion. Seven patients were in functional 
class III and five in class II at the time of study. Four patients 
were awaiting heart ransplantation. 
Seven patients had sinus rhythm and five had well con- 
trolled atrial fibrillation. The mean _+ SEM left ventricular 
ejection fraction was 26 _+ 2%. Seven patients were taking both 
diuretic drugs and an angiotensin-converting enzyme inhibitor; 
three patients were taking diuretic drugs only. One patient 
with severe ventricular dysfunction and mitral regurgitation 
required 80 mg day of furosemide to control heart failure but 
was able to stop taking diuretic drugs before inclusion in this 
study, having responded well to the introduction of captopril. 
Study protocol. Each patient received in double-blind, 
random order placebo r candoxatrilat doses of 50, 100 or 
200 mg administered by slow intravenous bolus over 5 rain at 
the same time of day on 4 separate days. Studies were at least 
48 h and usually 1 week apart (median 28 days from first to 
fourth study, range 11 to 63 days). Treatment order was 
determined by a computer-generated random code and used a 
balanced latin square design. Each patient served as his own 
control. 
Patients were placed on a diet containing 100 mmol of 
sodium and 40 mmol of potassium for 3 days before ach study 
day. A dietary history had determined that the usual median 
sodium intake of the study patients before this experiment was 
135 retool/day. Cardioactive medications were omitted on the 
morning of each study day. On arrival, the patient emptied the 
bladder, had standing blood pressure recorded and then 
remained supine until the end of the study day. Intravenous 
cannulas were inserted in antecubital veins bilaterally and the 
patient ate a set breakfast. After the patient had rested for 2 h, 
venous amples were taken for osmolality and hormone levels 
and he emptied the bladder again. Blood pressure was re- 
corded and the test drug was administered. 
Over the subsequent 8 h urinary samples were obtained 
every 2 h. Blood pressure was recorded at 1, 2 and 4 h after 
dosing. Three hours after dosing, the patient underwent radio- 
nuclide studies (see later) and a blood sample was taken for 
hormone assay. Under supervision, the patient was adminis- 
tered 200 ml of fluid in each 2-h period and a standardized 
light meal shortly after completion of the radionuclide studies. 
At the end of the study period, supine and standing blood 
pressure was recorded, and the patient was reexamined and 
discharged. 
Measurements. Heart rate was counted from the radial 
pulse, or cardiac apex for those with atrial fibrillation, and 
blood pressure was measured by using the same calibrated 
mercury sphygmomanometer. 
Urinary volume was measured and aliquots taken for 
measurement of cyclic guanosine monophosphate (GMP), 
sodium, potassium, magnesium, chloride, calcium, phosphate, 
urea, creatinine and osmolality. Urinary pH was measured by 
using Multistix (Ames). Urinary sodium and potassium levels 
were measured by using a Beckman E2A ISE analyzer; phos- 
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Table 2. Effects of Candoxatrilat on Urinary Volume, Electrolytes and Cyclic 
Guanosine Monophosphate 
Candoxatrilat 
p Value 
Urina U Variablcs Placebo 50 mg 100 mg 200 mg (pooled comparison) 
Volume (ml) 
0 -4h  230-+36 471 +51 '  466 + 71t 489 -+ 82t < 0.0001 
4 -8  h 293 + 46 356 + 44 397 + 60 369 + 49 < 0.01 
Sodium (±mol l  
0 -4  h 14 ± 4 31 -+ 7t 28 + 7t 37 + 115 < 0.0001 
4 -8  h 11 + 2 20 + 5 23 + 6t 20 + 4* < 0.001 
Chloride (mmol) 
0 -4  h 12 + 5 25 + 6~/ 21 + 6t 30 + 9:]: < 0.0001 
4 -8  h 8 + 3 15 _+ 5 16 + 5* 13 + 3 < 0.001 
Potassium (mmol) 
0 4 h 9-+ 1 12 + 2* 12-  1" 14 + 2* < 0.01 
4 -8h  9 -  + 1 8 + I 9 -1  9 + 1 NS 
Magnesium (±moll 
0-4  h 0.5 + 0.1 0.8 ± OAt 0.8 - 0.1t 0.8 + 0. l )  < 0.0001 
4 -8  h 0.5 ± 0.1 0.4 ± 0./) 0.6 - 0.1 0.5 + 0.1 NS 
Bicarbonate (±mol l  
0 -4  h 1.6 + 0.5 5.0 _+ 1.7t f).0 + 2.6t 5.0 _+ 1.8:]: < 0.0001 
4 -8  h 1.4 + 0.5 2.6 _+ 0,7 3.9 + 1.5' 3.0 + 0.9 < 0.0001 
Calcium (±mol l  
(1-4 h 0.6 -+ (I.1 1.1 _+ 0,2t 1.3 + 0.2+ 1.1 + 0.2t < 0.0001 
4 -8  h 0.5 _+ 0.l 0.5 _+ 0,1 0.7 + 0.1 0.7 _+ 0.1 <0.01 
Phosphate (mmol) 
0 -4  h 3.5 + 1).2 4.3 -+ 0,7 4.3 + 0.7 ~ 4.3 _+ 0.5* < 0.01 
4 -8  h 4.3 ± 0.4 3.3 + 0.4 4.7 + 1).5 4.2 + 0.4 NS 
Urea (mmol) 
0-4h  63+7 82 + 11' 84_+9 * 81 +9*  <0.001 
4 -8  h 68 + 8 63 + 7 74 + 7 69 + 6 NS 
Crcatinine (gmol) 
0 -4  h 1.7 +- 0.1 1.9 ± 0.2* 1.9 + 0.1' 2.0 _+ 0.2* < 0.001 
4 -8  h 2.0 + 0.1 1.7 + 0.2 2.0 ± 0.1 1.9 + 0.1 NS 
Cyclic GMP (pmol) 
l)-4 h 26 ± 5 82 - 15" 99 ± 19t 99 + 22t < 0.0001 
4 -8h  31 26  57-  11 80_  + l i t  91 + 13t < 0.0001 
*, t ,  $ indicatc differences of individual data points from values with placebo: *p < 0.05, tp < 0.0l, :]:p < 0.001. Data 
arc expressed as mean value = l SEM. GMP - guanosine monophosphate. 
phate, urea and creatinine by using the SMAC-2 analyzer 
(Technicon), and magnesium by using a Technicon RA-XT 
analyzer with proprietary agents. Chloride was measured on a 
CCMI chloride meter (Chemlab Sci Equipt) with Chemlab 
proprietary reagents. Osmolality was measured with a Clandon 
Scientific Osmomat. Urinary cyclic GMP was assayed by a 
double-antibody radioimmunoassay (Biomedical Technologies 
Inc.). 
Venous blood samples were drawn from the antecubital 
fossa on each day immediately before administration of can- 
doxatrilat and 3 h after dosing at the expected time of maximal 
effect. These samples were later assayed as previously de- 
scribed (2,13,14) for plasma renin activity, aldosterone, atrial 
natriuretic peptide and vasoactive intestinal polypeptide. In 
addition, 2-hourly samples were analyzed for plasma osmola- 
fity. 
Cardiac output was measured by standard technique (15) 
and renal blood flow was measured by using a first-pass 
technique from a bolus of 500 mBq of technetium-99m- 
labeled albumin (16). Renal blood flow to each kidney as a 
fraction of cardiac output was measured from the same 
first-pass dynamic data (16-18). Owing to the poor left ven- 
tricular function in these patients and a resulting wide bolus 
(19), the ratio of renal blood flow to cardiac output was based 
on a region of interest placed over the left ventricle and 
corrected for the lung signal from the base of the left lung (16). 
Total renal blood flow, expressed either as a percent of cardiac 
output or in absolute terms, was obtained by summing the 
values for the left and right kidneys. Renal vascular resistance 
was calculated from the renal blood flow and the mean arterial 
pressure. Left ventricular ejection fraction was obtained from 
the equilibrium phase of the injection with the use of gated 
acquisition over a minimum of 600 cardiac cycles within a 
defined representative RR interval on each occasion. Glomer- 
ular filtration rate was derived from the clearance of 5l- 
chromium ethylenediaminetetraacetic acid (20). 
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Figure 1. Plot of change in urinary volume, urinary cyclic guanosine 
monophosphate (GMP) and urinary sodium content over time after 
administration of placebo (circles) and candoxatrilat, 100 mg 
(squares). Variables are expressed asmean value ± t SE. 
Statistical analysis. The sample size of 12 patients was 
chosen as sufficient to detect a mean difference of 800 ml in 
cumulative urinary output (over 8 h) between placebo and any 
of the active treatment groups at the 5% level of significance 
with a p value >0.8. This calculation was based on the 
assumption that the within-patient standard deviation for 
urinary output on repeat occasions would be 798 ml in the 
absence of medication. In the light of the results of the study, 
the within-patient s andard eviation for urinary output was a 
gross overestimate; therefore, the study had the power to 
detect considerably smaller differences in urinary volume. 
Analysis of variance testing was applied, within-patient, for 
period, treatment and carryover effects. The treatment sums of 
squares were partitioned into orthogonal components due to 
1) pooled candoxatrilat versus placebo; 2) a linear dose- 
response relation for candoxatrilat; 3) a quadrantic dose 
response for candoxatrilat. The Dunnett statistic (21) was 
used, with values < 0.05 being considered significant. Values 
are presented as mean value _+ SEM. The primary statistical 
analysis compared the pooled results of active therapy (all 
three doses of candoxatrilat) versus placebo nly when analysis 
of variance had already indicated a treatment difference and 
that no difference among the effects of the three doses of 
candoxatrilat was present. Data for individual doses compared 
with placebo after correction for multiple comparisons are also 
shown. 
Results 
No significant differences were noted among the three 
doses of candoxatrilat for any measured variable. No effect of 
the order of treatment was noted. 
Urinary volume (Table 2, Fig. 1). Compared with placebo, 
candoxatrilat increased urinary volume over the 8 h. The 
diuresis occurred predominantly over the 1st 4 h, although 
effects persisted for at least 6 h after dosing. There was no 
relation between the dose of candoxatrilat and the urinary 
response. Oral fluid was administered at 100 ml/h on each 
study day (see Methods). A cumulative positive fluid balance 
occurred uring the placebo period, whereas fluid balance was 
negative during candoxatrilat s udy days. 
Urinary composition (Tables 2 and 3). Urinary sodium 
content increased, with the most striking effects observed in 
the 1st 4 h after candoxatrilat dministration, but an effect was 
sustained over the entire 8-h observation period. Urinary 
chloride excretion paralleled that of sodium. Urinary potas- 
sium increased in the 1st 4-h period, but the effect was not 
sustained. The excretion of potassium was not significantly 
increased over the 8 h of study. 
Candoxatrilat rendered the urine more alkaline than did 
placebo. Urinary magnesium, bicarbonate and calcium in- 
creased after candoxatrilat dministration, especially in the 1st 
4 h. Urinary phosphate, urea and creatinine increased only in 
the 1st 4-h collection period. Urinary osmolality decreased, 
reflecting a decline in urinary potassium, magnesium, phos- 
phate, urea and creatinine concentration. The urinary concen- 
tration of sodium, chloride and bicarbonate increased. 
The ratio of sodium, potassium, magnesium and bicarbon- 
ate to creatinine all increased in the 1st 4 h, reflecting 
increased fractional excretion of these electrolytes. The potas- 
sium/creatinine ratio was similar during placebo and active 
therapy during the 2nd 4-h period, but the ratio for other 
electrolytes remained elevated. The ratio of phosphate to 
creatinine was unchanged throughout the study, whereas the 
ratio of sodium to phosphate increased. 
Urinary cyclic GMP (Table 2). Urinary cyclic GMP in- 
creased markedly after each dose of candoxatrilat, but no 
significant difference between doses was observed. 
Hormones (Table 4). Plasma concentrations of atrial natri- 
uretic peptide (p < 0.001) and vasoactive intestinal polypep- 
tide (p = 0.01) increased, whereas those of aldosterone (p < 
0.01) were reduced. Plasma renin activity did not change. 
These effects were not dose related. 
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Table 3. Effects of Candoxatrilat on Urinary Osmolality and Excretion of Electrolytes 
Candoxatrilat 
p Value 
Placebo 50 mg 100 mg 200 mg (pooled comparison) 
738 + 93t 745 -- 69~ 777 ,+ 75* < 0.001 
641 + 77t 783 + 70* 823 -+ 86 < 0.05 
Osmolality (mOsm/kg) 
0 -4  h 992 + 101 
4 -8  h 937 _+ 108 
Sodium/creatinine (mmol/t~mol) 
0 -4h  8-+2 
4 -8h  6_+1 
Potassium/creatinine 
(mmol//xmol) 
0 -4  h 5.1 -+ 0.4 
4 -8  h 4.7 _+ 0.6 
Magnesium/creatinine 
([mmol × 100]/p, mol) 
0 -4  h 30 ,+ 4 
4 -8h  24±5 
Bicarbonate/creatinine 
(mmol//xmol) 
0 -4  h 0.9 + 0.3 
4 -8  h 0.7 + 0.2 
Phosphate/creatinine 
(mmol/~mol) 
0 -4  h 2.2 ,+ 0.2 
4 -8  h 2.3 + 0.1 
18 ± 4t 16 _+ 5t 19 + 6t < 0.0001 
12±2t  11 +3* 11 +2* <0.0001 
6.2 -+ 11.6 6.3 = {).6* 7.11 -+ 1.0t < 0.001 
4.7 + 0.5 4.3 + 0.5 5.0 ,+ 0.6 NS 
4l + 2t 42 + 4t 43 ,+ 3t < 0.0001 
34+4 * 33 + l* 34_+4 * <0.01 
2.5 : 0.7~ 3.0 _+ 1.1+ 2.4 --- 0.7t < 0.000l 
1.8 -+ 0.5 1.8 -+ 0.6 1.5 - 0.4 < 0.01 
2.3 ± 0.2 2.3 ± 0.2 2.2 ± 0.2 NS 
2.1 + 0.2 2.2 ,+ 0.2 2.4 -+ 0.3 NS 
*, t indicate differences of individual data points from values with placebo: *p < 0.05, tp < 0.01. Data are expressed 
as mean value ± 1 SEM. 
Heart rate and blood pressure (Table 5). Heart rate re- 
corded after administration of each dose of candoxatrilat did 
not differ from the rate recorded after placebo administration 
at any time. No significant change in blood pressure in either 
the supine or the standing position was observed after any dose 
of candoxatrilat. 
Ejection fraction and renal hemodynamic variables (Table 
6). Left ventricular ejection fraction and cardiac output were 
unchanged 3 h after candoxatrilat administration. Renal blood 
flow and glomerular filtration rate tended to increase with 
candoxatrilat and renal vascular resistance tended to decrease 
(p = NS). Renal blood flow expressed as a percent of cardiac 
output did increase. 
D iscuss ion  
To our knowledge this is the first comprehensive study of 
the acute renal response to neutral endopeptidase inhibition in 
patients with moderate to severe heart failure. Candoxatrilat 
produced a substantial increase in sodium and water excretion. 
Despite the diuresis, plasma atrial natriuretic peptide in- 
creased, there was no activation of the renin-angiotensin 
system and aldosterone decreased. Each dose of candoxatrilat 
provoked a similar diuresis and increase in plasma atrial 
natriuretic peptide, suggesting that all doses exceeded the 
minimal inhibitory concentration for neutral endopeptidase. 
Brief review of the effects of atrial natriuretic peptide in 
health and heart failure. The response to intravenous atrial 
natriuretic peptide in healthy subjects includes increases in 
urinary volume and sodium, phosphate, calcium, magnesium 
and chloride excretion (22). Reports of an increase in urinary 
potassium excretion have been inconsistent (9,23). An increase 
in hematocrit during infusion of atrial natriuretic peptide 
suggests a shift of fluid out of the intravascular compartment 
(9,24) that may, in part, be responsible for the decrease in 
cardiac filling pressures (22). Changes in cardiac output and 
Table 4. Effects of Candoxatrilat on Neuroendocrine Variables 
Candoxatrilat 
p Value 
Placebo 50 nag 100 mg 200 mg (pooled comparison) 
ANP (pg/ml) 140 + 26 263 ,+ 37t 320 + 65t 279 + 37t < 0.001 
Plasma renin activity 10.1 + L1 7.3 ,+ 1.9 9.2 ~ 2.1 11.9 _+ 2.6 NS 
(ng/ml per h) 
Aldosteronc (pg/mI) 178 _+ 41 108 ,+ 24* 1(13 + 26* 125 -- 35t < 0.01 
VIP (pmol/liter) 8.0 _+ 1.7 12.2 + 1,5 13.4 _+ 1.7' 11.5 _+ 2.0 0.01 
*, t indicate differences of individual data points from values with placebo: *p < 0.05, tp < 0.01. Data are expressed 
as mean value + I SEM. ANP - atrial natriuretic pcptidc; VIP = vasoactivc intestinal polypeptide. 
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Table 5. Effects of Candoxatrilat onHeart Rate and Blood Pressure 
Candoxatrilat 
Placebo 50 mg 100 mg 200 mg 
Heart rate (beats/min) 
4 h 76 + 4 76 +_ 4 74 + 4 76 + 4 
8h  78+_4 77+3 77+4 78+_4 
Supine BP (ram Hg) 
Systolic 
4 h 114 + 3 113 _+ 4 112_+ 4 1(18_+ 4 
8h 113+3 113-+3 111+6 110,+3 
Diastolic 
4h  74+_2 71 -2  69+_2 66+3 
8 h 77 + 2 74-+ 3 70 z 3 70 +_ 2 
Standing BP (ram Hg) 
Systolic 
8h  115+6 110+6 106+_5 107+6 
Diastolic 
8h  74+_3 72+_3 69-+3 68+_3 
Data are expressed as mean value _+ 1 SEM. There were no significant 
differences from values with placebo. BP blood pressure. 
systemic vascular esistance in response to atrial natriuretic 
peptide in normal subjects are small (9,23). 
In patients with heart failure the increase in urinary volume 
and natriuresis elicited by atrial natriuretic peptide is blunted 
(9) and kaliuresis is observed (23,25). Hematocrit does not 
increase during infusions of atrial natriuretic peptide for up to 
1 h in patients with heart failure (9,25), although during longer 
infusions it may increase (26), and in a previous tudy of heart 
failure candoxatrilat did not increase hematocrit (12). Unlike 
the urinary response, the vascular response to atrial natriuretic 
peptide is not grossly impaired in heart failure. Atrial natri- 
uretic peptide reduces ystemic vascular esistance and filling 
pressures and increases cardiac output (9,23). As hematocrit 
does not increase, a venodilator effect of atrial natriuretic 
peptide, possibly by inhibiting angiotensin II (27) or sympa- 
thetically mediated venous constriction (28,29), seems likely to 
account for the reduction in filling pressures. 
The reason for the attenuated renal response to atrial 
natriuretic peptide in human heart failure is not known. 
Among the mechanisms proposed are down-regulation of 
atrial natriuretic peptide receptors (30), changes in renal 
perfusion pressure (31,32) or intrarenal hemodynamic vari- 
ables and increased sympathetic a tivity (33,34). Alternatively, 
intraluminal degradation of atrial natriuretic peptide in the 
renal tubule may be increased as a result of either enzyme 
induction or a longer tubular transit ime allowing prolonged 
exposure and degradation fatrial natriuretic peptide before it 
can reach a more distal site of action. 
Potential mechanisms of the renal effects of eandoxatrilat. 
Although atrial natriuretic peptide antibodies abolish the renal 
response to candoxatril (35), atrial natriuretic peptide may not 
be the sole mediator of the renal response. Neutral endopep- 
tidase is capable of metabolizing a number of other peptides 
including bradykinin (37), brain natriuretic peptide (38), and, 
from the present study, vasoactive intestinal peptide. Interest- 
ingly, the renal response to brain natriuretic peptide, unlike 
that to atrial natriuretic peptide, may not be impaired in heart 
failure (38-41). Bradykinin and vasoactive intestinal peptide 
are also capable of stimulating a natriuresis (37,42). 
Filtered atrial natriuretic peptide and brain natriuretic 
peptide may exert heir effects on the inner medulla on their 
passage through the nephron rather than in the circulation. 
Receptors for atrial natriuretic peptide are found in the inner 
medullary collecting duct, whereas neutral endopeptidase is 
found in abundance in the brush border of the proximal tubule 
(43,44). Animal studies show that NEP inhibition protects 
atrial natriuretic peptide from degradation i the kidney and 
leads to the excretion of increased amounts of immunoreactive 
atrial natriuretic peptide (45). However, an increase in urinary 
atrial natriuretic peptide after candoxatrilat dministration has 
not been demonstrated in humans. 
Changes in urinary composition lend some insights into the 
renal effects of candoxatrilat. Urinary creatinine increased 
initially after administration f candoxatrilat, probably reflect- 
ing an increase in glomerular filtration rate, although this was 
not borne out by the radioisotope measurements of glomerular 
filtration rate. The ratio phosphate/creatinine, an index of 
reabsorption from the second half of the proximal tubule (46), 
was unaltered. Urinary potassium initially increased, as has 
been observed with atrial natriuretic peptide (23,25), but this 
increase did not persist, possibly owing to the suppression of 
plasma aldosterone. Magnesium and bicarbonate are reab- 
sorbed in both the proximal and the distal nephron (47), and 
Table 6. Hemodynamic Effects of Candoxatrilat at 3 Hours After Administration 
Candoxatrilat 
Placebo 50 mg 100 mg 200 mg 
GFR (ml/min) 72.0 + 8.2 78.3 z 9.3 89.3 - 8.2 76.0 -* 6.8 
RPF (ml/min) 298 _+ 50 378 _+ 65 379 = 64 305 - 25 
RBF/CO (dynes.s.cm s) 10.1 + 1.0 12.6 + 1.5 10.3 + 4.4 11.3 +- 1.2 (p = 0.053*) 
RVR (dynes.s.cm s) 0.36 _+ 0.05 0.27 +- 0.03 (I.31 _+ 0.06 0.29 + 0.03 
CO (liters/min) 3.0 +- 0.2 3.0 _+ 0.2 3.5 +- 0.2 2.7 + 0.2 
*p value comparing placebo and poolcd active therapy. There were no statistically significant differences between 
individual or pooled data points comparing placebo and candoxatrilat therapy. Data are expressed as mean value _+ l 
SEM. CO - cardiac output; GFR - glomerular filtration rate; RBF - renal blood flow; RPF = renal plasma flow; 
RVR = renal vascular esistance. 
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Table 7. Heterogeneity of Urinary Volume in Response toCandoxatrilat (0 to 4 h) 
Candoxatrilat 
Average Active 
Pt 50 mg 100 mg 200 mg Treatment 
No. Placebo (ml) (ml) (rnl) (ml) 
Average Increase 
With Candoxatrilat* 
ml % 
1 184 360 465 320 382 198 107 
2 124 312 352 243 302 178 144 
3 298 574 574 724 632 334 112 
4 534 900 1,038 1,199 1,046 512 96 
5 309 465 365 508 446 137 44 
6 176 541 824 722 696 520 295 
7 343 454 284 375 371 28 8 
8 210 605 412 430 482 272 130 
9 141 213 244 236 231 90 64 
10 215 401 267 264 311 96 44 
11 110 385 516 273 391 281 256 
12 115 430 250 569 416 301 262 
*Average active treatment value minus placebo value. Pt = patient. 
urinary content and fractional excretion, at least of the latter, 
were increased throughout the study. Overall, these data 
suggest that the initial increase in sodium excretion isdue to a 
combination of increased filtered load and effects distal to the 
proximal renal tubule. Later, the filtered load appears to 
return to normal, but distal tubular eabsorption of sodium in 
exchange for potassium is reduced secondary to effects on 
aldosterone. 
The present study failed to show an effect of candoxatrilat 
on renal blood flow. The technical variability in measuring 
absolute cardiac output and renal blood flow by our method 
may be large among patients with poor ventricular function, 
although comparisons with simultaneous thermodilution mea- 
surements have been favorable ven in such patients (48). The 
hemodynamic measurements were obtained over a short time 
3 h after the injection of candoxatrilat; we cannot say what 
blood flow measurements might have been at other times. Our 
results do not rule out an effect on renal blood flow and, 
indeed, when this flow is expressed as a percent of cardiac 
output, the data suggest that it is increased after candoxatrilat. 
The reasons why some patients responded better than 
others to candoxatrilat re uncertain from the present study. 
No baseline variable, treatment regime, neuroendocrine or 
renal hemodynamic response was clearly related to the mag- 
nitude of response (Tables 1 and 7). Further studies to 
determine which factors are responsible for the heterogeneity 
in response are needed. 
Potential advantages of neutral endopeptidase inhibitors 
over conventional diuretic agents. Until the last decade, con- 
ventional diuretic agents were the only generally accepted 
highly effective agents for the management of congestive heart 
failure. These agents lessen the symptoms and signs of heart 
failure (49) and are essential for the management of acute 
heart failure, but there are no trials to test their impact on 
prognosis. Conventional diuretic agents are attended by many 
side effects such as diabetes and gout, and activation of the 
renin-angiotensin system. Conventional diuretic therapy re- 
duces plasma atrial natriuretic peptide, impairing a compen- 
satory mechanism resisting sodium retention (50-52). The 
neuroendocrine effects associated with conventional diuretic 
drugs may reduce their long-term effectiveness, lead to accel- 
eration in the decline of ventricular function and increase the 
incidence of arrhythmias and sudden death. A diuretic agent 
such as candoxatrilat that simulated the actions of atrial 
natriuretic peptide, provoking a diuresis and simultaneous 
inhibition of neuroendocrine activation, could have consider- 
able therapeutic potential for the treatment of heart failure. 
Limitations of the present study. There is little experience 
as yet with neutral endopeptidase inhibitors in human heart 
failure. At the time of inception of the study we believed that 
the doses we had chosen would span the therapeutic range of 
the drug; however, all the doses we used appeared to be at the 
top of the dose-response curve. We may also be criticized for 
not measuring cardiac and renal hemodynamies directly by 
invasive means. We considered this impossible given the study 
design. Moreover the primary objective of the study was to 
assess the effects of candoxatrilat on urinary volume. 
We cannot say what the magnitude of the urinary response 
to candoxatrilat is in patients with heart failure compared with 
that of normal subjects (53), although in this study it was 
similar to that observed in mild heart failure (11). Studies in 
rats suggest that heart failure may augment the diuretic effects 
of candoxatrilat, an effect hat was attributed to higher levels 
of atrial natriuretic peptide (54). These results must be ex- 
trapolated with caution to human heart failure; the effect 
of candoxatrilat may be augmented in untreated human 
heart failure but long-term diuretic therapy and possibly 
angiotensin-converting e zyme inhibitors may reduce this ef- 
fect by decreasing atrial natriuretic peptide (55). 
Treatment before the study was heterogeneous, a factor 
that may have influenced the results, although we did not 
observe such effects. However, each patient acted as his own 
control and withheld his usual medication similarly on each 
study day. Even if the effects of angiotensin-converting enzyme 
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inhibition had persisted into the study, they would not have 
invalidated these placebo-controlled results. 
Conclusions. Candoxatrilat causes a diuresis in patients 
with moderately severe heart failure, increasing atrial natri- 
uretic peptide and vasoactive intestinal polypeptide and sup- 
pressing aldosterone without activating the renin-angiotensin 
system. The mechanism of the changes in salt and water 
excretion remains to be fully elucidated, but the present study 
suggests that the predominant effects are an increase in the 
filtered load of sodium and on the nephron distal to the 
proximal tubule. There is an as yet unexplained heterogeneous 
response among patients. The effects of candoxatrilat in heart 
failure are worthy of further investigation. 
We are grateful to Gau, Frost for dietary counseling of our patients. 
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